
Supplementary information

Income group	RT Age cohort		Threshold cost per fully vaccinated person																	
		To be cost-effective at varying thresholds													To be cost caving					
		Health opportunity costs						GPD per capita						To be cost-saving						
		Pharyngitis	RHD	Invasive	Impetigo	Cellulitis	All	Pharyngitis	RHD	Invasive	Impetigo	Cellulitis	All	Pharyngitis	RHD	Invasive	Impetigo	Cellulitis	All	
HIC	rt0	\$143.7	\$7.0	\$67.1	\$152.9	\$28.5	\$399.3	\$142.4	\$5.8	\$55.9	\$152.8	\$28.3	\$385.2	\$137.0	\$0.4	\$8.0	\$152.2	\$27.3	\$324.9	
HIC	rt5	\$311.0	\$8.2	\$15.9	\$132.9	\$28.3	\$496.3	\$308.3	\$6.7	\$13.2	\$132.8	\$28.0	\$489.0	\$296.4	\$0.5	\$1.7	\$132.3	\$27.0	\$458.0	
UMIC	rt0	\$28.8	\$82.6	\$7.1	\$32.5	\$0.9	\$151.8	\$29.3	\$139.2	\$11.2	\$32.5	\$0.9	\$213.1	\$28.2	\$10.3	\$1.9	\$32.4	\$0.9	\$73.6	
UMIC	rt5	\$62.6	\$128.7	\$1.7	\$28.3	\$0.8	\$222.0	\$63.7	\$216.3	\$2.6	\$28.3	\$0.8	\$311.7	\$61.3	\$16.8	\$0.4	\$28.2	\$0.7	\$107.5	
LMIC	rt0	\$17.4	\$13.8	\$1.1	\$3.1	\$0.3	\$35.7	\$17.7	\$50.3	\$2.9	\$3.1	\$0.3	\$74.3	\$17.4	\$7.4	\$0.8	\$3.1	\$0.3	\$29.0	
LMIC	rt5	\$38.6	\$25.0	\$0.3	\$2.7	\$0.3	\$66.9	\$39.1	\$88.9	\$0.7	\$2.7	\$0.3	\$131.8	\$38.5	\$13.8	\$0.2	\$2.7	\$0.3	\$55.4	
LIC	rt0	\$7.6	\$9.3	\$0.5	\$1.3	\$0.1	\$18.8	\$7.7	\$26.9	\$1.0	\$1.3	\$0.1	\$37.1	\$7.6	\$5.1	\$0.4	\$1.3	\$0.1	\$14.5	
LIC	rt5	\$17.0	\$17.6	\$0.1	\$1.2	\$0.1	\$36.0	\$17.1	\$50.0	\$0.2	\$1.2	\$0.1	\$68.7	\$16.9	\$9.9	\$0.1	\$1.2	\$0.1	\$28.2	


Supplementary Table 1. Threshold costs per fully vaccinated person to be cost-effective and cost-saving (default efficacy rates scenario)

Supplementary Figure 1. Threshold cost per fully vaccinated person to be cost-effective by income group




Scenario 2


Scenario 3




Scenario 4




Scenario 5




Scenario 6





Supplementary Figure 2. Threshold cost per fully vaccinated person to be cost-effective by scenario: 20% reduction of the default efficacy rate scenario

The lower bounds are based on the least favorable scenario: 20% wastage rate, lower bound of economic burden, and 3% discounting of health outcomes. The upper bounds are for the most favorable scenario: 5% wastage rate, upper bound of economic burden, and 0% discounting of health outcomes.



Supplementary Figure 3. Threshold cost per fully vaccinated person to be cost-effective by scenario: 40% reduction of the default efficacy rate scenario


The lower bounds are based on the least favorable scenario: 20% wastage rate, lower bound of economic burden, and 3% discounting of health outcomes. The upper bounds are for the most favorable scenario: 5% wastage rate, upper bound of economic burden, and 0% discounting of health outcomes.



Supplementary Figure 4. Threshold cost per fully vaccinated person to be cost-effective by scenario: 60% reduction of the default efficacy rate scenario

The lower bounds are based on the least favorable scenario: 20% wastage rate, lower bound of economic burden, and 3% discounting of health outcomes. The upper bounds are for the most favorable scenario: 5% wastage rate, upper bound of economic burden, and 0% discounting of health outcomes.



















Supplementary Figure 6. Additional multivariate analyses

